| 000 | 01890 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517044256.0 | ||
| 264 | 0 | _c20160620 | |
| 008 | 201606s 0 0 eng d | ||
| 022 | _a1873-2518 | ||
| 024 | 7 |
_a10.1016/j.vaccine.2015.06.103 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPerrett, Kirsten P | |
| 245 | 0 | 0 |
_aImmune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. _h[electronic resource] |
| 260 |
_bVaccine _cSep 2015 |
||
| 300 |
_a5217-24 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 |
_aAntibodies, Bacterial _xblood |
| 650 | 0 | 4 |
_aAntigens, Bacterial _ximmunology |
| 650 | 0 | 4 | _aAustralia |
| 650 | 0 | 4 | _aBlood Bactericidal Activity |
| 650 | 0 | 4 | _aCanada |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aComplement System Proteins |
| 650 | 0 | 4 |
_aDrug-Related Side Effects and Adverse Reactions _xepidemiology |
| 650 | 0 | 4 | _aEnzyme-Linked Immunosorbent Assay |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunization Schedule |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMeningococcal Infections _ximmunology |
| 650 | 0 | 4 |
_aMeningococcal Vaccines _xadministration & dosage |
| 650 | 0 | 4 |
_aNeisseria meningitidis, Serogroup B _ximmunology |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aMcVernon, Jodie | |
| 700 | 1 | _aRichmond, Peter C | |
| 700 | 1 | _aMarshall, Helen | |
| 700 | 1 | _aNissen, Michael | |
| 700 | 1 | _aAugust, Allison | |
| 700 | 1 | _aPercell, Sandra | |
| 700 | 1 | _aToneatto, Daniela | |
| 700 | 1 | _aNolan, Terry | |
| 773 | 0 |
_tVaccine _gvol. 33 _gno. 39 _gp. 5217-24 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.vaccine.2015.06.103 _zAvailable from publisher's website |
| 999 |
_c25129787 _d25129787 |
||